898563-00-3

Basic information

• Product Name: 2-{4-[4-Pyridin-4-yl-1-(2,2,2-trifluoro-ethyl)-1H-pyrazol-3-yl]-phenoxymethyl}-quinoline
• Synonyms: 2-{4-[4-Pyridin-4-yl-1-(2,2,2-trifluoro-ethyl)-1H-pyrazol-3-yl]-phenoxymethyl}-quinoline;TP-10
• CAS NO: 898563-00-3
• Molecular Formula: C26H19F3N4O
• Molecular Weight: 460
• EINECS: 604-604-1
• Mol File: 898563-00-3.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-{4-[4-Pyridin-4-yl-1-(2,2,2-trifluoro-ethyl)-1H-pyrazol-3-yl]-phenoxymethyl}-quinoline(CAS DataBase Reference)
• NIST Chemistry Reference: 2-{4-[4-Pyridin-4-yl-1-(2,2,2-trifluoro-ethyl)-1H-pyrazol-3-yl]-phenoxymethyl}-quinoline(898563-00-3)
• EPA Substance Registry System: 2-{4-[4-Pyridin-4-yl-1-(2,2,2-trifluoro-ethyl)-1H-pyrazol-3-yl]-phenoxymethyl}-quinoline(898563-00-3)

Safety Data

• Hazardous Substances Data: 898563-00-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2-4-[4-Pyridin-4-yl-1-(2,2,2-trifluoro-ethyl)-1H-pyrazol-3-yl]-phenoxymethyl-quinoline is used as a pharmaceutical compound for its potential pharmacological activities. The presence of various functional groups and the trifluoroethyl substituent in its structure may contribute to its efficacy in treating certain conditions or diseases.
Further research and testing are required to fully understand the potential uses and effects of this chemical, as its complex structure suggests a wide range of possible applications. The exploration of its properties and interactions with biological systems will be crucial in determining its suitability and safety for use in medicinal applications.

Upstream product

• 871507-11-8 2-((4-(4-(pyridin-4-yl)-1H-pyrazol-5-yl)phenoxy)methyl)quinoline 
• 353-83-3 1,1,1-trifluoro-2-iodoethane 
• 871507-16-3 3-(dimethylamino)-2-(pyridin-4-yl)-1-(4-(quinolin-2-ylmethoxy)phenyl)prop-2-en-1-one 
• 5042-30-8 2,2,2,trifluoroethylhydrazine 

Relevant articles and documents

METHODS FOR TREATING DISEASES OF THE RETINA

Disclosed herein is a method of treating disorders of the retina comprising administering to a patient in need of such treatment a therapeutically effective amount of a compound of Formula I as defined herein. These compounds are useful as PDE10 inhibitors.

Discovery of a novel class of phosphodiesterase 10A inhibitors and identification of clinical candidate 2-[4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3- yl)-phenoxymethyl]-quinoline (PF-2545920) for the treatment of schizophrenia

By utilizing structure-based drug design (SBDD) knowledge, a novel class of phosphodiesterase (PDE) 10A inhibitors was identified. The structure-based drug design efforts identified a unique "selectivity pocket" for PDE10A inhibitors, and interactions within this pocket allowed the design of highly selective and potent PDE10A inhibitors. Further optimization of brain penetration and drug-like properties led to the discovery of 2-[4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline (PF-2545920). This PDE10A inhibitor is the first reported clinical entry for this mechanism in the treatment of schizophrenia.

Heteroaromatic quinoline compounds

The invention pertains to heteroaromatic compounds that serve as effective phosphodiesterase (PDE) inhibitors. In particular, the invention relates to said compounds which are selective inhibitors of PDE10. The invention also relates to intermediates for preparation of said compounds; pharmaceutical compositions comprising said compounds; and the use of said compounds in a method for treating certain central nervous system (CNS) or other disorders.